- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- CIPLA - TTK HEALTHCARE
CIPLA vs TTK HEALTHCARE - Comparison Results
Current Valuations
| CIPLA | TTK HEALTHCARE | CIPLA/ TTK HEALTHCARE |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 39.8 | 22.0 | 180.7% | View Chart |
| P/BV | x | 3.7 | 7.4 | 49.4% | View Chart |
| Dividend Yield | % | 0.5 | 0.4 | 118.1% |
Financials
 CIPLA  TTK HEALTHCARE |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| CIPLA Mar-18 |
TTK HEALTHCARE Mar-14 |
CIPLA/ TTK HEALTHCARE |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 663 | 663 | 99.9% | |
| Low | Rs | 479 | 399 | 120.1% | |
| Sales per share (Unadj.) | Rs | 189.0 | 535.6 | 35.3% | |
| Earnings per share (Unadj.) | Rs | 17.6 | 15.9 | 110.3% | |
| Cash flow per share (Unadj.) | Rs | 34.0 | 20.0 | 169.9% | |
| Dividends per share (Unadj.) | Rs | 3.00 | 4.00 | 75.0% | |
| Dividend yield (eoy) | % | 0.5 | 0.8 | 69.8% | |
| Book value per share (Unadj.) | Rs | 176.7 | 137.6 | 128.4% | |
| Shares outstanding (eoy) | m | 805.12 | 7.77 | 10,361.9% | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 3.0 | 1.0 | 304.6% | |
| Avg P/E ratio | x | 32.5 | 33.3 | 97.4% | |
| P/CF ratio (eoy) | x | 16.8 | 26.5 | 63.3% | |
| Price / Book Value ratio | x | 3.2 | 3.9 | 83.7% | |
| Dividend payout | % | 17.1 | 25.1 | 68.0% | |
| Avg Mkt Cap | Rs m | 459,724 | 4,127 | 11,138.3% | |
| No. of employees | `000 | 23.6 | 1.7 | 1,382.3% | |
| Total wages/salary | Rs m | 26,901 | 607 | 4,434.7% | |
| Avg. sales/employee | Rs Th | 6,446.1 | 2,436.7 | 264.5% | |
| Avg. wages/employee | Rs Th | 1,139.4 | 355.2 | 320.8% | |
| Avg. net profit/employee | Rs Th | 600.0 | 72.5 | 827.1% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 152,193 | 4,162 | 3,656.9% | |
| Other income | Rs m | 3,577 | 61 | 5,844.0% | |
| Total revenues | Rs m | 155,769 | 4,223 | 3,688.6% | |
| Gross profit | Rs m | 28,264 | 197 | 14,339.8% | |
| Depreciation | Rs m | 13,228 | 32 | 41,729.3% | |
| Interest | Rs m | 1,142 | 30 | 3,820.4% | |
| Profit before tax | Rs m | 17,470 | 197 | 8,881.4% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | -28 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -775 | 0 | - | |
| Tax | Rs m | 2,501 | 73 | 3,435.6% | |
| Profit after tax | Rs m | 14,166 | 124 | 11,433.2% | |
| Gross profit margin | % | 18.6 | 4.7 | 392.1% | |
| Effective tax rate | % | 14.3 | 37.0 | 38.7% | |
| Net profit margin | % | 9.3 | 3.0 | 312.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 108,141 | 1,629 | 6,639.7% | |
| Current liabilities | Rs m | 38,322 | 1,058 | 3,622.8% | |
| Net working cap to sales | % | 45.9 | 13.7 | 334.4% | |
| Current ratio | x | 2.8 | 1.5 | 183.3% | |
| Inventory Days | Days | 97 | 30 | 325.8% | |
| Debtors Days | Days | 74 | 34 | 221.5% | |
| Net fixed assets | Rs m | 109,411 | 556 | 19,667.7% | |
| Share capital | Rs m | 1,610 | 78 | 2,072.3% | |
| "Free" reserves | Rs m | 140,682 | 878 | 16,017.5% | |
| Net worth | Rs m | 142,292 | 1,069 | 13,307.0% | |
| Long term debt | Rs m | 36,621 | 159 | 23,075.7% | |
| Total assets | Rs m | 228,606 | 2,399 | 9,527.6% | |
| Interest coverage | x | 16.3 | 7.6 | 215.0% | |
| Debt to equity ratio | x | 0.3 | 0.1 | 173.4% | |
| Sales to assets ratio | x | 0.7 | 1.7 | 38.4% | |
| Return on assets | % | 6.7 | 6.4 | 104.5% | |
| Return on equity | % | 10.0 | 11.6 | 85.9% | |
| Return on capital | % | 10.0 | 18.5 | 53.9% | |
| Exports to sales | % | 32.8 | 0.8 | 4,146.1% | |
| Imports to sales | % | 0 | 1.4 | 0.0% | |
| Exports (fob) | Rs m | 49,883 | 33 | 151,619.1% | |
| Imports (cif) | Rs m | NA | 58 | 0.0% | |
| Fx inflow | Rs m | 51,691 | 33 | 157,115.2% | |
| Fx outflow | Rs m | 21,033 | 63 | 33,285.8% | |
| Net fx | Rs m | 30,658 | -30 | -101,213.6% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 14,628 | 127 | 11,554.2% | |
| From Investments | Rs m | -8,540 | -146 | 5,849.4% | |
| From Financial Activity | Rs m | -3,855 | 22 | -17,601.8% | |
| Net Cashflow | Rs m | 2,431 | 3 | 97,244.0% | |
Share Holding
| Indian Promoters | % | 16.0 | 65.4 | 24.5% | |
| Foreign collaborators | % | 20.8 | 0.0 | - | |
| Indian inst/Mut Fund | % | 12.2 | 3.7 | 329.7% | |
| FIIs | % | 23.7 | 5.2 | 455.8% | |
| ADR/GDR | % | 1.1 | 0.0 | - | |
| Free float | % | 26.2 | 25.8 | 101.6% | |
| Shareholders | 161,166 | 12,723 | 1,266.7% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CIPLA With: IPCA LABS SANOFI INDIA ALEMBIC PHARMA PFIZER NATCO PHARMA
Compare CIPLA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)
Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.
Related Views on News
TTK HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Down 276.0% (Quarterly Result Update)
Aug 13, 2018 | Updated on Aug 13, 2018For the quarter ended June 2018, TTK HEALTHCARE has posted a net profit of Rs 79 m (down 276.0% YoY). Sales on the other hand came in at Rs 2 bn (up 38.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)
Aug 10, 2018 | Updated on Aug 10, 2018For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)
Aug 8, 2018Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why
Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)
Aug 9, 2018Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...
Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)
Aug 7, 2018Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.
Why HDFC Equity Fund Disappointed Its Investors(Outside View)
Aug 9, 2018Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.
HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)
Aug 8, 2018PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.
More|
| |
CIPLA SHARE PRICE
Aug 17, 2018 (Close)
TRACK CIPLA
- Track your investment in CIPLA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CIPLA
CIPLA 5-YR ANALYSIS
COMPARE CIPLA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.